Literature DB >> 11432110

Improvement of IVF outcome in poor responders by discontinuation of GnRH analogue during the gonadotropin stimulation phase--a function of improved embryo quality.

M Schachter1, S Friedler, A Raziel, D Strassburger, O Bern, R Ron-el.   

Abstract

PURPOSE: To assess the efficacy of a protocol involving the discontinuation of the GnRH analogue at the mid-phase of ovarian stimulation for IVF in patients with a previous poor response.
METHODS: Prospective case-control evaluation compared with same patient's previous performance. Thirty-six patients enrolled in an IVF program were treated in two consecutive cycles. The first with a standardized protocol utilizing midluteal administration of Nafarelin (N) 600 mcg/d continued throughout the stimulation phase with human menopausal gonadotropin (hMG) until follicles of 20 mm were identified by transvaginal ultrasound (Standard group). Patients with a poor response in the Standard cycle were treated in the subsequent cycle with N and hMG initially in a similar manner, then N was stopped after 5 days of hMG stimulation (N-stop group). All clinical and laboratory aspects of treatment were done in a similar fashion in both cycles, each patient acting as her own control.
RESULTS: Results were analyzed by paired t test. The change in each parameter in the N-stop cycle was expressed as the percent change as compared with the standard protocol cycle for each patient. Peak estradiol (E2) and number of aspirated oocytes were increased in the N-stop cycle (+16.9% and +28%, respectively), but insignificantly so. The percent of cleaving embryos was significantly increased by 27.9% (p = 0.03) in the N-stop cycle, as embryo morphology was improved by 22% (p = 0.02). The efficacy of gonadotropin treatment was enhanced in the N-stop cycle, as expressed by a 32.5% increase in oocytes retrieved per hMG ampoule administered (p = 0.04). Three cycles of 36 were cancelled during the N-stop cycle, whereas only one was cancelled in the standard protocol cycle. Of the 36 patients, 7 conceived in the N-stop protocol and 5 are ongoing pregnancies.
CONCLUSION: Discontinuation of GnRH-a during ovarian stimulation for IVF has a beneficial, but not statistically significant, effect on both E2 and oocyte production. Embryo cleavage rates and morphology were significantly improved, this may be due to improved oocyte quality, which may have been responsible for achieving pregnancies. The efficacy of gonadotropin treatment was enhanced when GnRH-a was discontinued. These results hint that GnRH-a may have a direct negative effect on folliculogenesis and oocytes, which is apparent especially in poor responder patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11432110      PMCID: PMC3455367          DOI: 10.1023/a:1009476411762

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  37 in total

1.  Gonadotropin stimulation following GnRH-a priming for poor responders in in vitro fertilization-embryo transfer programs.

Authors:  H Pinkas; R Orvieto; O M Avrech; O Rufas; A Ferber; Z Ben-Rafael; B Fisch
Journal:  Gynecol Endocrinol       Date:  2000-02       Impact factor: 2.260

2.  Direct effect of gonadotropin-releasing hormone agonists on the rabbit ovarian follicle.

Authors:  Y Yoshimura; Y Nakamura; M Ando; S Shiokawa; N Koyama; T Nanno
Journal:  Fertil Steril       Date:  1992-05       Impact factor: 7.329

3.  GnRH receptors in human granulosa cells: anatomical localization and characterization by autoradiographic study.

Authors:  J Latouche; M Crumeyrolle-Arias; D Jordan; N Kopp; B Augendre-Ferrante; L Cedard; F Haour
Journal:  Endocrinology       Date:  1989-09       Impact factor: 4.736

4.  Human oviductal gonadotropin-releasing hormone: possible implications in fertilization, early embryonic development, and implantation.

Authors:  E M Casañ; F Raga; F Bonilla-Musoles; M L Polan
Journal:  J Clin Endocrinol Metab       Date:  2000-04       Impact factor: 5.958

5.  The role of gonadotropin-releasing hormone in murine preimplantation embryonic development.

Authors:  F Raga; E M Casañ; J Kruessel; Y Wen; F Bonilla-Musoles; M L Polan
Journal:  Endocrinology       Date:  1999-08       Impact factor: 4.736

6.  Insulin-like growth factor-II mediates the steroidogenic and growth promoting actions of follicle stimulating hormone on human ovarian pre-antral follicles cultured in vitro.

Authors:  W Yuan; L C Giudice
Journal:  J Clin Endocrinol Metab       Date:  1999-04       Impact factor: 5.958

7.  Short-term luteinizing hormone-releasing hormone agonist treatment: prospective trial of a novel ovarian stimulation regimen for in vitro fertilization.

Authors:  M C Macnamee; C M Howles; R G Edwards; P J Taylor; K T Elder
Journal:  Fertil Steril       Date:  1989-08       Impact factor: 7.329

8.  Cessation of gonadotropin-releasing hormone analogue (GnRH-a) upon down-regulation versus conventional long GnRH-a protocol in poor responders undergoing in vitro fertilization.

Authors:  M Dirnfeld; O Fruchter; D Yshai; A Lissak; A Ahdut; H Abramovici
Journal:  Fertil Steril       Date:  1999-09       Impact factor: 7.329

9.  The effect of gonadotrophin-releasing hormone (GnRH) agonist in the follicular phase on in-vitro fertilization outcome in normo-ovulatory women.

Authors:  J Smitz; E Van Den Abbeel; N Bollen; M Camus; P Devroey; H Tournaye; A C Van Steirteghem
Journal:  Hum Reprod       Date:  1992-09       Impact factor: 6.918

10.  Interval required for gonadotropin-releasing hormone-agonist-induced down regulation of the pituitary in cynomolgus monkeys and duration of the refractory state.

Authors:  K L Winslow; K Gordon; R F Williams; G D Hodgen
Journal:  Fertil Steril       Date:  1992-12       Impact factor: 7.329

View more
  8 in total

1.  Effect of estrogen priming through luteal phase and stimulation phase in poor responders in in-vitro fertilization.

Authors:  Eun Mi Chang; Ji Eun Han; Hyung Jae Won; You Shin Kim; Tae Ki Yoon; Woo Sik Lee
Journal:  J Assist Reprod Genet       Date:  2011-12-08       Impact factor: 3.412

2.  A novel "delayed start" protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders.

Authors:  Hakan Cakmak; Nam D Tran; A Musa Zamah; Marcelle I Cedars; Mitchell P Rosen
Journal:  Fertil Steril       Date:  2014-03-14       Impact factor: 7.329

Review 3.  Different ovarian stimulation protocols for women with diminished ovarian reserve.

Authors:  D Loutradis; P Drakakis; E Vomvolaki; A Antsaklis
Journal:  J Assist Reprod Genet       Date:  2007-11-22       Impact factor: 3.412

4.  Maximum basal FSH predicts reproductive outcome better than cycle-specific basal FSH levels: waiting for a "better" month conveys limited retrieval benefits.

Authors:  Julian A Gingold; Joseph A Lee; Michael C Whitehouse; Jorge Rodriguez-Purata; Benjamin Sandler; Lawrence Grunfeld; Tanmoy Mukherjee; Alan B Copperman
Journal:  Reprod Biol Endocrinol       Date:  2015-08-15       Impact factor: 5.211

Review 5.  Management of poor responders in IVF: is there anything new?

Authors:  Filippo Ubaldi; Alberto Vaiarelli; Rosario D'Anna; Laura Rienzi
Journal:  Biomed Res Int       Date:  2014-07-20       Impact factor: 3.411

6.  Pregnancy outcome of "delayed start" GnRH antagonist protocol versus GnRH antagonist protocol in poor responders: A clinical trial study.

Authors:  Abbas Aflatoonian; Aflatoonian Hosseinisadat; Ramesh Baradaran; Maryam Farid Mojtahedi
Journal:  Int J Reprod Biomed       Date:  2017-04

7.  Strategies for Pituitary Down-regulation to Optimize IVF/ICSI Outcome in Poor Ovarian Responders.

Authors:  Ahmed Badawy; Alaa Wageah; Mohamed El Gharib; Ezz Eldin Osman
Journal:  J Reprod Infertil       Date:  2012-07

8.  Prediction and diagnosis of poor ovarian response: the dilemma.

Authors:  Ahmed Badawy; Alaa Wageah; Mohamed El Gharib; Ezz Eldin Osman
Journal:  J Reprod Infertil       Date:  2011-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.